| ADA kicks off GLP-1 succession saga
|
(Amylin Pharmaceuticals)
|
10-Jun-2008 |
| Entereg(R) (alvimopan) Available for the Management of Postoperative Ileus
|
(Adolor)
|
09-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Eli Lilly)
|
09-Jun-2008 |
| Targanta Submits Marketing Authorization Application for Oritavancin
|
(Targanta Therapeutics)
|
09-Jun-2008 |
| ADA - DPP-IVs and GLP-1s steal the show
|
(Merck & Co)
|
09-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Alkermes)
|
09-Jun-2008 |
| After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight
|
(Amylin Pharmaceuticals)
|
09-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Eli Lilly)
|
07-Jun-2008 |
| Monotherapy BYETTA® (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
|
(Eli Lilly)
|
07-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Alkermes)
|
07-Jun-2008 |
| Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
|
(Amylin Pharmaceuticals)
|
07-Jun-2008 |
| Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
(Amylin Pharmaceuticals)
|
07-Jun-2008 |
| Lilly Submits Cymbalta® Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
|
(Eli Lilly)
|
29-May-2008 |
| Study Showed ALIMTA® (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
|
(Eli Lilly)
|
28-May-2008 |
| BioMS Medical’s Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
27-May-2008 |
| Adolor and GlaxoSmithKline Announce FDA Approval of Entereg(R) (alvimopan) for the Management of Postoperative Ileus (POI)
|
(Adolor)
|
20-May-2008 |
| ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
|
(Eli Lilly)
|
15-May-2008 |
| Adolor Provides Regulatory Update on Entereg(R) (alvimopan)
|
(Adolor)
|
09-May-2008 |
| FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents
|
(Eli Lilly)
|
08-May-2008 |
| Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
|
(AstraZeneca)
|
04-May-2008 |
| Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment
|
(Vertex Pharmaceuticals)
|
24-Apr-2008 |
| Teva Announces Tentative Approval of Generic Evista® Tablets
|
(Teva Pharmaceutical Industries)
|
17-Apr-2008 |
| Anthera Presents Data on Varespladib at ATVB Meeting
|
(Anthera Pharmaceuticals)
|
17-Apr-2008 |
| DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
|
(Anthera Pharmaceuticals)
|
16-Apr-2008 |
| BioMS Medical’s Phase III U.S. Multiple Sclerosis Trial Receives Positive Safety Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
15-Apr-2008 |
| ALIMTA® (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
|
(Eli Lilly)
|
11-Apr-2008 |
| Targanta Announces FDA Acceptance of Oritavancin New Drug Application
|
(Targanta Therapeutics)
|
09-Apr-2008 |
| Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
|
(Eli Lilly)
|
31-Mar-2008 |
| New Data Showed ACTOS® (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes
|
(Takeda)
|
31-Mar-2008 |
| Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
|
(Eli Lilly)
|
29-Mar-2008 |
| Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
|
(Daiichi Sankyo)
|
29-Mar-2008 |
| New Studies Confirm the Benefits of Dapoxetine as a Treatment of Premature Ejaculation
|
(Johnson & Johnson)
|
27-Mar-2008 |
| MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
|
(AstraZeneca)
|
18-Mar-2008 |
| Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
|
(Genaera)
|
18-Mar-2008 |
| No Sign of ANDA Filing for Daptomycin
|
(Cubist Pharmaceuticals)
|
13-Mar-2008 |
| Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients
|
(Vertex Pharmaceuticals)
|
13-Mar-2008 |
| Akorn-Strides, LLC Announces FDA Approval for Tobramycin Injection USP, 80 mg/2mL and 1.2 grams/30mL
|
(Akorn)
|
12-Mar-2008 |
| MannKind - last gasp for inhaled insulin
|
(Alkermes)
|
10-Mar-2008 |
| Alkermes Receives Notice from Eli Lilly Terminating Inhaled Insulin Program
|
(Alkermes)
|
07-Mar-2008 |
| Lilly Announces Termination of AIR Insulin Program
|
(Eli Lilly)
|
07-Mar-2008 |
| Sun Pharma Gets USFDA Tentative Approval for Generic Gemzar® Injection
|
(Sun Pharmaceutical Industries)
|
05-Mar-2008 |
| BioMS Medical’s Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
|
(BioMS Medical)
|
03-Mar-2008 |
| NPIL Research & Development Limited Commences Phase I Trials on New Molecule for Metabolic Disorders in Europe
|
(Piramal Healthcare)
|
29-Feb-2008 |
| FORSTEO® Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis
|
(Eli Lilly)
|
22-Feb-2008 |
| FDA decision strengthens chance of prasugrel approval
|
(Eli Lilly)
|
22-Feb-2008 |
| Lilly Launches KwikPen™ for Humalog® and Humalog Mixtures
|
(Eli Lilly)
|
21-Feb-2008 |
| FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, Prasugrel
|
(Eli Lilly)
|
21-Feb-2008 |
| FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
|
(Daiichi Sankyo)
|
21-Feb-2008 |
| Daiichi Sankyo, Lilly Submit Marketing Authorization Application for Investigational Oral Antiplatelet Drug, Prasugrel, to European Medicines Agency
|
(Daiichi Sankyo)
|
20-Feb-2008 |
| NRDL Announces Second Drug Development Agreement With Eli Lilly and Company
|
(Piramal Healthcare)
|
15-Feb-2008 |
| FDA Extends Review of NDA for ENTEREG(R) (alvimopan)
|
(Adolor)
|
08-Feb-2008 |
| FDA Advisory Committee Supports Efficacy and Safety of Zyprexa® Long-Acting Injection (LAI) for Schizophrenia Treatment
|
(Eli Lilly)
|
06-Feb-2008 |
| MedImmune Submits Biologics License Application to FDA for Motavizumab
|
(AstraZeneca)
|
04-Feb-2008 |
| Adolor and GlaxoSmithKline Report Favorable FDA Advisory Committee Meeting for ENTEREG(R) (alvimopan) for the Management of Postoperative Ileus in Bowel Resection
|
(Adolor)
|
23-Jan-2008 |
| U.S. Federal Trade Commission Clears Global Licensing and Development Agreement Between BioMS Medical and Lilly
|
(BioMS Medical)
|
23-Jan-2008 |
| Adolor Announces Availability of Briefing Documents For January 23rd FDA Advisory Committee Meeting on Entereg(R) (alvimopan)
|
(Adolor)
|
18-Jan-2008 |
| Inhaled insulin running out of puff?
|
(Novo Nordisk)
|
15-Jan-2008 |
| Anthera Announces Preliminary Positive Results from Once-Daily A-002 Phase II Cardiovascular Trial
|
(Anthera Pharmaceuticals)
|
15-Jan-2008 |
| FDA Approves Cialis® (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction
|
(Eli Lilly)
|
08-Jan-2008 |
| Which of this year's launches will be future blockbusters?
|
(Roche)
|
04-Jan-2008 |
| Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
|
(Eli Lilly)
|
04-Jan-2008 |
| Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
|
(Daiichi Sankyo)
|
04-Jan-2008 |
| Anthera’s A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease.
|
(Anthera Pharmaceuticals)
|
18-Dec-2007 |
| Submission of Marketing Authorisation Application for Dapoxetine in Europe
|
(Johnson & Johnson)
|
07-Dec-2007 |
| Monotherapy BYETTA® Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
|
(Eli Lilly)
|
06-Dec-2007 |
| Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
|
(Eli Lilly)
|
06-Dec-2007 |
| Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
|
(Amylin Pharmaceuticals)
|
06-Dec-2007 |
| FDA Approves Cymbalta® for Maintenance Treatment of Major Depressive Disorder
|
(Eli Lilly)
|
30-Nov-2007 |
| Cardiome Initiates Phase 1 Study for GED-aPC
|
(Cardiome Pharma)
|
20-Nov-2007 |
| FORTEO® Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
|
(Eli Lilly)
|
14-Nov-2007 |
| Olanzapine from Actavis First to Market in Germany
|
(Actavis)
|
07-Nov-2007 |
| Prasugrel convinces markets even if doubts remain
|
(Daiichi Sankyo)
|
05-Nov-2007 |
| In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
|
(Daiichi Sankyo)
|
04-Nov-2007 |
| In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
|
(Eli Lilly)
|
04-Nov-2007 |
| Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
|
(Eli Lilly)
|
04-Nov-2007 |
| Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
|
(Daiichi Sankyo)
|
04-Nov-2007 |
| First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
|
(Vertex Pharmaceuticals)
|
02-Nov-2007 |
| Novo Nordisk should play Liraglutide time advantage
|
(Novo Nordisk)
|
01-Nov-2007 |
| Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
|
(Eli Lilly)
|
31-Oct-2007 |
| Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
|
(Daiichi Sankyo)
|
24-Oct-2007 |
| Anthera Announces Positive Phase II Clinical Results from A-002 Cardiovascular Disease Trial
|
(Anthera Pharmaceuticals)
|
24-Oct-2007 |
| Lilly and MacroGenics Announce Licensing and Collaboration Agreement
|
(Eli Lilly)
|
18-Oct-2007 |
| Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
|
(Eli Lilly)
|
05-Oct-2007 |
| Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
|
(Anthera Pharmaceuticals)
|
03-Oct-2007 |
| Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
|
(Caraco Pharmaceutical Laboratories)
|
26-Sep-2007 |
| Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
|
(Eli Lilly)
|
25-Sep-2007 |
| One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
|
(Eli Lilly)
|
21-Sep-2007 |
| Lilly Files for European Approval of ALIMTA® (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
|
(Eli Lilly)
|
20-Sep-2007 |
| FDA Approves Lilly's Osteoporosis Drug EVISTA® (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
|
(Eli Lilly)
|
14-Sep-2007 |
| Cubicin® Receives European Approval to Expand Use to Treating Two Additional Types of Life-threatening Hospital Infections
|
(Novartis)
|
05-Sep-2007 |
| Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
|
(Eli Lilly)
|
02-Sep-2007 |
| FDA Accepts for Review Complete Response to Approvable Letter for Entereg(R) (alvimopan) for POI
|
(Adolor)
|
28-Aug-2007 |
| FDA Accepts for Review Complete Response to Approvable Letter for Entereg®(Alvimopan) for POI
|
(GlaxoSmithKline)
|
28-Aug-2007 |
| New Data Suggest Cymbalta® Reduced Pain in Fibromyalgia Patients with and without Depression
|
(Eli Lilly)
|
21-Aug-2007 |
| FDA Advisory Committee Recommends Approval of EVISTA for the Reduction of Risk for Invasive Breast Cancer in Two Populations of Postmenopausal Women
|
(Eli Lilly)
|
24-Jul-2007 |
| BYETTA® - First in a New Class of Medicines for Treatment of Type 2 Diabetes - Is Accepted by Scottish Medicines Consortium for Use Before Patients Start Insulin Therapy
|
(Eli Lilly)
|
11-Jul-2007 |
| Anthera Completes Enrollment of “PLASMA” Trial With A-002 and Announces Initiation of New Investigator Study
|
(Anthera Pharmaceuticals)
|
02-Jul-2007 |
| BYETTA® Study Showed Sustained Blood Glucose Control Over Three Years in People with Type 2 Diabetes
|
(Eli Lilly)
|
25-Jun-2007 |
| BYETTA® Study Showed Comparable Blood Glucose Control to Insulin
|
(Eli Lilly)
|
24-Jun-2007 |
| BYETTA® Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
|
(Eli Lilly)
|
23-Jun-2007 |
| Corcept Therapeutics Announces Positive Results From Its Proof of Concept Study Evaluating the Ability of CORLUX(R) to Mitigate Weight Gain Associated With Olanzapine
|
(Corcept Therapeutics)
|
21-Jun-2007 |
| Barr Announces Withdrawal of ZYPREXA(R) Zydis(R) Patent Litigation
|
(Barr Pharmaceuticals)
|
11-Jun-2007 |
